NAD+
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme in every cell, offered by clinics as injections and IV drips, though no NAD+ injection is FDA-approved.
US regulatory status
Compounding restricted
No NAD+ injection is approved by the FDA. NAD is in Category 1 of the FDA’s interim 503A policy (list updated May 14, 2026), so state-licensed pharmacies may compound it under certain conditions while the FDA evaluates it; that is not an approval, and the FDA has warned compounders against making IV NAD+ from food-grade ingredients.
At a glance
- Also known as
- Nicotinamide adenine dinucleotide, Beta-NAD, Nadide
- Supplied as
- Several forms, depending on the product
- Research
- Limited human evidence
- US status
- US status: Restrictedchecked
What the research shows
Evidence grade
Limited human evidence
Some studies in people, but they are small, short, early-phase or uncontrolled.
NAD+ is a coenzyme cells need for energy metabolism and DNA repair, and in model organisms its levels fall in some tissues with age. In people, recent large studies found that whole-blood NAD+ does not decline with healthy aging itself. A 2026 systematic review of 113 studies (33 in humans, 80 in rodents) found no outcome trials of intravenous or intramuscular NAD+ for aging or wellness; oral precursors such as NR and NMN raised NAD markers, but effects on health outcomes were mixed and often null. A 2026 review of IV NAD+ found mostly small, uncontrolled studies and case reports, and judged the evidence insufficient to support routine clinical or wellness use. In a small 6-hour infusion study, plasma NAD+ did not change for the first 2 hours because it was rapidly and completely removed from the plasma.
How we grade evidence
Strong human evidence
Consistent results from large randomized controlled trials in people.
Limited human evidence · this page
Some studies in people, but they are small, short, early-phase or uncontrolled.
Mixed evidence
Studies in people disagree, or strong evidence for one use sits beside weak evidence for another.
Animal or lab studies only
Studied in cells or animals, not properly in people. Animal results may not apply to humans.
The grade describes how much research exists and in whom. It is not a judgment that a compound works or is safe.
Side effects and safety
Reported side effects of IV NAD+ include nausea, cramping, flushing and chest discomfort, and long-term safety data are lacking. The FDA has warned that some compounders made IV NAD+ from food-grade powder, which can carry microbes and endotoxins, and it has received reports of severe chills, shaking, vomiting and fatigue after NAD+ injections, some needing medical treatment. NAD+ injections have been recalled for elevated endotoxin (a Class I recall) and for lack of sterility assurance. The FDA generally advises using multi-dose vials of sterile medicine within 28 days of first use.
Vial math
Pre-filled calculators turn your vial, water and prescribed dose into syringe units.
Pre-filled for your vial size
- NAD+ 500 mgReconstitution calculator
- NAD+ 1,000 mgReconstitution calculator
- Any vial sizePeptide reconstitution calculator
This is arithmetic, not medical advice. Confirm with your prescriber or pharmacist.
Questions people ask
What are NAD+ injections?
They deliver nicotinamide adenine dinucleotide, a coenzyme every cell uses to make energy, as a shot under the skin (subcutaneous), into a muscle (intramuscular) or as an IV drip. Clinics and compounding pharmacies offer them. No NAD+ injection is an FDA-approved drug, and a 2026 systematic review found no outcome trials of IV or intramuscular NAD+ for aging or wellness.
Sources
- Nat Rev Mol Cell Biol, 2021: NAD(+) metabolism and its roles in cellular processes during ageing (opens in a new tab)
- Ageing Res Rev, 2026: NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence (opens in a new tab)
- U.S. Food and Drug Administration, 2026: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (updated May 14, 2026) (opens in a new tab)
Is NAD+ a peptide?
No. NAD+ is a coenzyme, a small molecule (C21H27N7O14P2, molecular weight 663.4) rather than a chain of amino acids. It is often offered alongside peptides, which is why people search for it as one. It also behaves differently in a vial: it dissolves very easily in water, and vials hold hundreds of mg rather than a few.
Are NAD+ injections FDA-approved?
No. The FDA lists NAD and a reduced form, NADH, in Category 1 of its 503A compounding policy. While it decides whether to add them to the official list, the FDA does not intend to take action against a state-licensed pharmacy that compounds them under the policy’s conditions. That is not an approval of any product. One salt form, beta-NAD disodium salt trihydrate, sits in Category 3, which does not get that policy.
Sources
- U.S. Food and Drug Administration, 2026: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (updated May 14, 2026) (opens in a new tab)
- U.S. Food and Drug Administration, 2026: Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (opens in a new tab)
Do NAD+ injections work?
There is no good evidence yet. A 2026 systematic review found no outcome trials of injected or IV NAD+ for aging or wellness, and a 2026 review of IV NAD+ found mostly small, uncontrolled studies. Raising NAD+ in the blood is also not simple: in one infusion study, plasma levels did not change for the first 2 hours.
Sources
- Ageing Res Rev, 2026: NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence (opens in a new tab)
- Front Aging, 2026: Narrative review of intravenous NAD(+) and NAD(+) precursors in wellness and translational medicine (opens in a new tab)
- Front Aging Neurosci, 2019: A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD (opens in a new tab)
What are the side effects of NAD+ injections?
Reports on IV NAD+ describe nausea, cramping, flushing and chest discomfort. Separately, the FDA has received reports of severe chills, shaking, vomiting and fatigue after NAD+ injections and says these reactions are consistent with excessive endotoxin levels, a sign of contamination; and NAD+ injections have been recalled for elevated endotoxin and for lack of sterility assurance. Long-term safety has not been studied.
Sources
- Front Aging, 2026: Narrative review of intravenous NAD(+) and NAD(+) precursors in wellness and translational medicine (opens in a new tab)
- U.S. Food and Drug Administration, 2024: FDA reminds compounders to use ingredients suitable for sterile compounding (opens in a new tab)
- U.S. Food and Drug Administration, 2025: FDA Enforcement Report (openFDA drug enforcement): recalls D-0094-2026 (Class I), D-0065-2026, D-0478-2025, D-0487-2025, NAD+ injections (opens in a new tab)
How much bacteriostatic water do I mix with a 500 mg NAD+ vial?
There is no single correct amount. The water only sets the concentration: mg in the vial ÷ mL of water = mg per mL. For example (numbers for illustration only, not a dose), 500 mg of NAD+ in 5 mL makes 100 mg/mL, so each unit on a U-100 insulin syringe holds 1 mg. The same vial in 10 mL makes 50 mg/mL, or 0.5 mg (500 mcg) per unit. More water means each unit holds less; less water means each unit holds more. The reconstitution calculator does this arithmetic for your vial. Many NAD+ vials are already liquid (FDA recall listings show 50 to 200 mg/mL in 10 mL vials), so check the pharmacy label first and add nothing to a liquid. If it is a powder, the label or your pharmacist sets the volume.
Sources
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (updated May 14, 2026)U.S. Food and Drug Administration, 2026 · Accessed Oct 16, 2026 (opens in a new tab)
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C ActU.S. Food and Drug Administration, 2026 · Accessed Oct 16, 2026 (opens in a new tab)
- FDA reminds compounders to use ingredients suitable for sterile compoundingU.S. Food and Drug Administration, 2024 · Accessed Oct 16, 2026 (opens in a new tab)
- NAD(+) metabolism and its roles in cellular processes during ageingNat Rev Mol Cell Biol, 2021 · Accessed Oct 16, 2026 (opens in a new tab)
- Narrative review of intravenous NAD(+) and NAD(+) precursors in wellness and translational medicineFront Aging, 2026 · Accessed Oct 16, 2026 (opens in a new tab)
- NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidenceAgeing Res Rev, 2026 · Accessed Oct 16, 2026 (opens in a new tab)
- A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NADFront Aging Neurosci, 2019 · Accessed Oct 16, 2026 (opens in a new tab)
- FDA Enforcement Report (openFDA drug enforcement): recalls D-0094-2026 (Class I), D-0065-2026, D-0478-2025, D-0487-2025, NAD+ injectionsU.S. Food and Drug Administration, 2025 · Accessed Oct 16, 2026 (opens in a new tab)
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight LossU.S. Food and Drug Administration, 2026 · Accessed Oct 16, 2026 (opens in a new tab)
- Nadide (NAD+), CID 5892PubChem, National Library of Medicine (NIH) · Accessed Oct 16, 2026 (opens in a new tab)
Related compounds
Guides
Every medical and regulatory statement on this page links to a checkable source, listed above. Peptinote does arithmetic and education, not medical advice, and never sells or links to sellers of peptides.